by Michael D. O’Neill, MA, February 24, 2026
Dhruvajyoti Roy, PhD, has built a distinguished career spanning over a decade in biomarker discovery, assay development, and the clinical translation of innovative diagnostic platforms for cancer care. He has systematically advanced ultrasensitive molecular detection technologies from fundamental nanoscience principles to validated clinical diagnostic platforms. His career trajectory—spanning from atomic force microscopy (AFM) breakthroughs to multi-analyte blood tests for early cancer detection—demonstrates how visionary science can be transformed into life-saving clinical tools.
From Nanoscale Innovation to Clinical Reality: The AFM Story
Dr. Roy’s early career established him as a leader in ultrasensitive biomarker detection. While he was a graduate student at Pohang university of Science and Technology (POSTECH) in South Korea he successfully implemented force-based AFM for single molecule detection of biomarkers.1-3 He was the key scientist to design and develop dendron-coated AFM tips and surfaces for detection of various disease related biomarkers and translated the technology for commercial applications. His success with those innovative methods resulted in widespread acclaim in the broader field of endeavor beyond several applications areas including detection of microRNA, chronic myeloid leukemia biomarkers, DNA biomarkers without amplification. His seminal work provided the analytical foundation for single-molecule immunodetection in clinical settings.
These publications were not merely academic exercises; they formed the scientific basis for commercial implementation of AFM-based diagnostics in clinical laboratory environments, validating the technology’s reliability and reproducibility for patient testing. This technology successfully bridged the gap between academic innovation and commercial implementation, establishing AFM as a viable tool for ultrasensitive biomarker detection in clinical diagnostics. Dr. Roy spearheaded the development and optimization of the proprietary NanoCone™ chemistry and NanoCone Enabled Atomic Force (NE-AFM™) technology—an industry-leading platform for single-molecule detection. What distinguishes Dr. Roy’s work is not merely scientific innovation, but successful implementation of AFM technology in commercial diagnostic services. His research demonstrated that force-based AFM could reliably detect individual antigens captured on antibody microarray platforms—a critical validation step for clinical adoption.
From Early Detection to Treatment Monitoring: Liquid Biopsy Based Multi-Analyte Approach
Dr. Roy also represents the modern paradigm of translational oncology research—a scientist equally comfortable at the bench developing ultrasensitive detection methodologies and in the clinic implementing validated assays for patient care. His expertise in liquid biopsy, multi-analyte biomarker integration, and clinical trial design positions him as a key contributor to the ongoing revolution in cancer diagnostics. Through his work on circulating tumor cells, circulating tumor DNA, extracellular vesicles (EVs), and multi-omics integration, Dr. Roy is advancing the field toward a future where cancer detection, monitoring, and treatment guidance are increasingly precise, non-invasive, and personalized—ultimately improving outcomes for cancer patients worldwide. Dr. Roy’s methodological sophistication extends to multi-omics integration—combining genomic, epigenomic, transcriptomic, and proteomic data to construct comprehensive biomarker signatures.
A landmark achievement includes the development of a proprietary platform for accurate and efficient detection of cell-free DNA methylation patterns from blood, identifying unique biomarkers that signal cancer presence.5,6 This innovation culminated in the launch of a multi-analyte blood test for early detection of hepatocellular carcinoma (HCC)—a clinically validated tool that exemplifies his translational vision. Dr. Roy’s most transformative contribution to early cancer detection emerged through his development of a proprietary DNA methylation platform for identifying unique cancer biomarkers from blood samples. Recognizing that epigenetic modifications offer distinctive signatures of malignant transformation, Dr. Roy spearheaded the development of cell-free DNA methylation patterns as biomarkers for non-invasive cancer detection. This innovation culminated in a US Patent and more significantly, the assay was clinically validated and launched as a multi-analyte blood test for early detection of HCC and implemented this technology in a CLIA/CAP-certified laboratory for clinical services—a critical milestone that transformed a promising research discovery into a clinically actionable diagnostic tool.
Dr. Roy’s research has added significant value to the cancer diagnostics field, and he is continuously implementing his work through collaborative research. Among his recent achievements is a pivotal collaborative study published in BMC Cancer examining longitudinal monitoring of circulating tumor cell dynamics for potential prediction of early recurrence and clinical outcomes after curative resection of hepatocellular carcinoma.7 This pilot study represents a critical advancement in understanding how dynamic changes in CTC populations can serve as early warning signals for disease recurrence in HCC patients. The research demonstrates Dr. Roy’s commitment to translating biomarker science into actionable clinical insights. The work not only underscores the clinical value of longitudinal liquid biopsy but also reflects Dr. Roy’s collaborative and broader research initiatives, which span multiple platforms for analyzing liquid biopsy based multi-analytes for cancer diagnostics.
While the HCC study is modest in scale, it fits into a much larger body of work from Dr. Roy’s research focused on liquid biopsy technologies across cancer types. Over the past decade, Dr. Roy has established and validated multiple methods for analyzing diverse analytes from liquid biopsy, including CTCs, circulating tumor DNA (ctDNA), cell-free DNA methylation patterns, extracellular vesicles, and other biomarkers. These platforms have been applied to a range of cancers, including liver, lung, breast, colorectal, prostate, and pancreatic cancers, with a particular emphasis on early detection, therapy monitoring, and recurrence surveillance. By tracking CTC dynamics over time in post-surgical HCC patients, the study provides evidence that serial CTC monitoring may identify patients at high risk for recurrence before conventional imaging detects disease progression. This approach aligns with the emerging paradigm of liquid biopsy-driven surveillance, offering patients and clinicians a non-invasive, blood-based tool for early intervention. His liquid biopsy expertise extends across multiple cancer types and clinical scenarios while his career trajectory reflects a commitment to democratizing access to advanced cancer diagnostics from bench to bedside through integrative liquid biopsy approaches.
References:
- Roy, D., Kwon, S. H., Kwak, J.-W., and Park, J. W. (2010). “Seeing and counting” individual antigens captured on a microarrayed spot with force-based atomic force microscopy. Anal. Chem. 82, 5189–5194. doi: 10.1021/ac100476b
- Roy, D.; Kwak, J.-W.; Maeng, W.J.; Kim, H.; Park, J.W. Dendron-modified polystyrene microtiter plate: Surface characterization with picoforce AFM and influence of spacing between immobilized amyloid beta proteins. Langmuir 2008, 24, 14296–14305.
- Roy, D.; Park, J.W. Spatially nanoscale-controlled functional surfaces toward efficient bioactive platforms. J. Mater. Chem. B 2015, 3, 5135–5149.
- Roy, D.; Taggart, D.; Zheng, L.; Liu, D.; Li, G.; Li, M.; Zhang, K.; Etten, R.A.V. Abstract 837: Circulating cell-free DNA methylation assay: Towards early detection of multiple cancer types. Cancer Res. 2019, 79, 837.
- Roy D, Xu J, Taggart DJ, et al.: A prospective clinical trial to evaluate the performance of a multi-analyte blood test for early detection of hepatocellular carcinoma among at-risk patients with liver cirrhosis: The CLiMB study. J Clin Oncol. 2023, 41:617. 10.1200/JCO.2023.41.4_suppl.TPS617
- Roy, D. & Tiirikainen, M. Diagnostic power of DNA methylation classifiers for early detection of cancer. Trends cancer 6, 78–81 (2020).
- Roy, D., Guckelberger, O., Oppermann, E. et al. Longitudinal monitoring of circulating tumor cell dynamics for potential prediction of early recurrence and clinical outcomes after curative resection of hepatocellular carcinoma: a pilot study. BMC Cancer (2026). https://doi.org/10.1186/s12885-026-15638-7